Arrowhead Pharmaceuticals (NASDAQ:ARWR) Announces Quarterly Earnings Results

Arrowhead Pharmaceuticals (NASDAQ:ARWR) announced its quarterly earnings data on Tuesday. The biotechnology company reported ($1.36) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.13), FiscalAI reports. The company had revenue of $75.25 million for the quarter, compared to analyst estimates of $44.17 million. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. Arrowhead Pharmaceuticals’s revenue for the quarter was up 171.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.26) EPS.

Here are the key takeaways from Arrowhead Pharmaceuticals’ conference call:

• Phase III SHASTA-3 and SHASTA-4 both met all primary and prespecified secondary endpoints, with median triglyceride reductions of 79% and 81% and a 78% reduction in pooled acute pancreatitis events versus placebo. Arrowhead reported a 100% reduction in events among the highest-risk subgroup, though detailed data remain subject to the upcoming ESC presentation.
• REDEMPLO’s U.S. FCS launch continued to gain traction, with prescriptions more than doubling sequentially, over 400 unique prescribers, and approximately $2.4 million in quarterly commercial revenue. The company also reported approvals in Australia and the European Union, expanding its approved footprint to five geographies.
• Arrowhead acquired a priority review voucher for $215 million, which it expects could shorten FDA review of the planned SHTG supplemental NDA from 10 months to six months. The company plans to submit the sNDA by the end of 2026 and is preparing to expand its field organization from about 5,000 to more than 20,000 healthcare-provider targets.
• The pipeline has several potential catalysts, including September data for ARO-DIMER-PA and the ARO-MAPT CNS delivery program, plus fourth-quarter updates for ARO-INHBE and ARO-ALK7. Management expects 23 candidates in clinical trials by year-end, but most programs remain early-stage and carry substantial development risk.
• Arrowhead’s quarterly net loss widened to $194.3 million from $175.2 million year over year, while operating expenses rose to approximately $245 million as R&D and commercialization investments increased. The company held about $1.6 billion in cash and investments, but expects continued spending on clinical development, regulatory work, manufacturing, and potential SHTG launch preparation.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR stock traded up $3.58 during trading on Tuesday, hitting $89.59. The company’s stock had a trading volume of 2,031,077 shares, compared to its average volume of 2,293,102. The company has a market cap of $12.62 billion, a PE ratio of -41.67 and a beta of 1.27. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 1.41. The business has a fifty day moving average of $79.48 and a 200-day moving average of $71.01. Arrowhead Pharmaceuticals has a 52 week low of $15.01 and a 52 week high of $95.49.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on ARWR shares. JPMorgan Chase & Co. upped their price target on Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Chardan Capital boosted their price target on shares of Arrowhead Pharmaceuticals from $90.00 to $115.00 and gave the company a “buy” rating in a research note on Wednesday, July 22nd. Piper Sandler reaffirmed an “overweight” rating and issued a $126.00 price objective (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research note on Thursday, July 23rd. Stifel Nicolaus initiated coverage on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, July 14th. They set a “buy” rating and a $98.00 target price for the company. Finally, Sanford C. Bernstein raised their price target on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. Nine investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Arrowhead Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $96.92.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, Director Hongbo Lu sold 2,970 shares of the business’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total value of $228,333.60. Following the transaction, the director owned 52,012 shares of the company’s stock, valued at approximately $3,998,682.56. The trade was a 5.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.60% of the company’s stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. Invesco Ltd. increased its holdings in Arrowhead Pharmaceuticals by 8.9% in the 4th quarter. Invesco Ltd. now owns 547,758 shares of the biotechnology company’s stock worth $36,366,000 after acquiring an additional 44,866 shares during the last quarter. Corient Private Wealth LLC raised its holdings in Arrowhead Pharmaceuticals by 3.1% during the 4th quarter. Corient Private Wealth LLC now owns 18,226 shares of the biotechnology company’s stock valued at $1,210,000 after acquiring an additional 551 shares during the period. Mercer Global Advisors Inc. ADV bought a new stake in Arrowhead Pharmaceuticals during the 4th quarter valued at $352,000. Summit Global Investments lifted its position in shares of Arrowhead Pharmaceuticals by 43.8% during the fourth quarter. Summit Global Investments now owns 14,287 shares of the biotechnology company’s stock worth $949,000 after acquiring an additional 4,353 shares in the last quarter. Finally, State of Tennessee Department of Treasury lifted its position in shares of Arrowhead Pharmaceuticals by 2.0% during the fourth quarter. State of Tennessee Department of Treasury now owns 55,642 shares of the biotechnology company’s stock worth $3,858,000 after acquiring an additional 1,092 shares in the last quarter. Institutional investors own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.